Vimarsana
Biggest News Aggregation in the World

Page 11 - Mark Womack News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Womack. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Womack Today - Breaking & Trending Today

Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA (pegloticase injection) at AGC's Copenhagen Facility - Vimarsana News

Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA (pegloticase injection) at AGC's Copenhagen Facility

(1) Seattle, April 30, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the expansion of their partnership with Horizon Therapeutics plc (Nasdaq: HZNP), to include the manufacturing of KRYSTEXXA (pegloticase injection) - a biologic medicine for treatment of chronic gout refractory to conventional therapies (uncontrolled gout), at its state-of-the-art facility in Copenhagen, Denmark. "We are extremely happy to further expand our strategic partnership with Horizon by leveraging the microbial capacity...

Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase ... - Vimarsana News

Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase ... AGC BiologicsApril 30, 2021 GMT Seattle, April 30, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the expansion of their partnership with Horizon Therapeutics plc (Nasdaq: HZNP), to include the manufacturing of KRYSTEXXA® (pegloticase injection) – a biologic medicine for treatment of chronic gout refractory ...

Source: apnews.com
Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase injection) at AGC's Copenhagen Facility - Vimarsana News

Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase injection) at AGC's Copenhagen Facility

Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase injection) at AGC’s Copenhagen Facility Seattle, April 30, 2021 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the expansion of their partnership with Horizon Therapeutics plc (Nasdaq: HZNP), to include the manufacturing of KRYSTEXXA® (pegloticase injection) – a biologic medicine for treatment of chronic gout refractory to conventional therapies (uncontrolled gout), at its state-of-the-art facility in Copen...

Novavax says supply shortages delaying full-speed production... - Vimarsana News

Novavax says supply shortages delaying full-speed production...

By Carl O'Donnell April 13 (Reuters) - Novavax Inc has pushed back the timeline for hitting its production target of 150 million COVID-19 vaccine doses per month until the third quarter due to supply shortages including bags used to grow cells, a company spokeswoman told Reuters. Novavax executives had previously said full-scale vaccine production could be achieved by mid-year. The company told Reuters in January it expected to reach full production capacity by May or June. "We said during our earnings call that we expect all capacity being online by around mid-year. We're continuing to refin...

Source: trust.org
Novavax COVID-19 vaccine production set back due to supply shortages - Vimarsana News

Novavax COVID-19 vaccine production set back due to supply shortages

Novavax COVID-19 vaccine production set back due to supply shortages Posted 5 AprApril 2021 at 2:06pm Data released in March from the UK trial showed the vaccine to be highly effective against COVID-19. ( Print text only Cancel Novavax Inc has pushed back the timeline for hitting its production target of 150 million COVID-19 vaccine doses per month until the third quarter due to supply shortages, dealing another blow to the federal government's rollout plans. Key points: Novavax is one of three companies the federal government struck a deal with to distribute COVID-19 vaccines in Australia...

Source: abc.net.au